Travelzoo

This management proposal asks stockholders to approve a 600,000-share nonqualified stock option (the HB Option) granted to Global CEO Holger Bartel with an exercise price of $5.05 and bi-annual vesting from June 30, 2026 through December 31, 2027. Management is seeking shareholder approval because the option is subject to stockholder approval before it may be exercised and the issuance of underlying Common Stock must be authorized and registered; the Compensation Committee also engaged an independent consultant (Compensia) and unanimously approved the grant. The proposal should be viewed in the context of retention and incentive dynamics: management states that a significant portion of the CEO’s prior option compensation had vested and was partly underwater, and the Committee considered market benchmarking and total compensation positioning versus a customized peer group. The grant’s size (600,000 options) is material relative to the company’s outstanding shares (10.9% beneficial for CEO’s holdings noted elsewhere) and could have dilution and governance implications, particularly given concentrated ownership by Azzurro Capital. The vesting schedule is time-based (four bi-annual tranches), so the grant ties CEO incentive to multi-year tenure rather than explicit performance metrics; this raises questions about alignment versus pure pay-for-performance design. The Board and Compensation Committee’s unanimous recommendation and use of an independent consultant provide governance cover, but shareholders should weigh the grant size, exercise price relative to market, and lack of performance vesting conditions. Termination provisions provide limited post-termination exercisability windows (90 days) and standard transferability restrictions; tax and registration contingencies further limit near-term dilution. Overall, the proposal seeks to rebalance CEO compensation to support retention and incentive alignment, but investors should consider dilution, the absence of performance-based vesting, the company’s recent TSR and net income trends, and the relationship between this grant and prior option grants when deciding whether to support it.

This management proposal requests shareholder approval of a 50,000-share nonqualified stock option (JB Option) for Jason Bushman, the Company’s General Manager, U.S., with an exercise price of $7.14 (Nasdaq close on Dec 29, 2025) and four annual vesting tranches starting Sept 1, 2026. Management requires stockholder approval before the option may be exercised and the shares registered, and the Compensation Committee has reviewed and recommended the grant. The grant size is modest relative to the company’s outstanding shares and is intended primarily for retention and alignment of the U.S. general manager’s interests with long-term shareholder value. Like the CEO grant, the JB Option is time-based (annual vesting) and does not include performance-based vesting conditions, so alignment with performance will depend on future stock price and company results rather than explicit targets. Exercise, transferability and post-termination exercise provisions are standard (90-day post-termination window for vested options), and the option includes customary anti-dilution adjustments and registration contingencies. Shareholders should weigh the retention rationale and market benchmarking cited by the Compensation Committee against the absence of explicit performance vesting and the potential dilution. The Board’s unanimous recommendation and the independent consultant’s involvement support governance prudence, but investors should consider how this grant fits within total executive pay and long-term incentive design.

This management proposal requests shareholder approval of a 50,000-share nonqualified stock option (AH Option) for Azar Hashemi, the Company’s Head of Engineering, with an exercise price of $6.28 (Nasdaq close on March 4, 2026) and four annual vesting tranches beginning March 4, 2027. Shareholder approval is required before the option may be exercised and the shares registered; the Compensation Committee approved the grant and recommends shareholder support. The grant is intended for retention and alignment of the engineering leader with the company’s long-term performance, and its size is modest relative to total share count, limiting dilution risk. The award is time-vested rather than performance-vested, which means the alignment with company performance relies on future stock price appreciation instead of predefined operational or financial targets. The option includes standard terms—anti-dilution adjustments, transfer restrictions, and a 90-day exercise window after termination for vested amounts—and is subject to registration and approval contingencies. Investors should assess this grant in the context of the company’s broader equity program and compensation philosophy (below-median total target vs. peers) and consider whether time-based vesting adequately motivates performance in a senior technical role. Given the Board and Compensation Committee’s unanimous recommendation and consultant benchmarking, the proposal is governance-supported, but shareholders should factor in dilution, lack of performance conditions, and how this grant integrates into total executive and key-employee compensation.

This is a routine, non-binding advisory 'say-on-pay' proposal asking shareholders to approve the disclosure and design of executive compensation for named executive officers as presented in the proxy. Management frames its compensation program as judgment-based, using the Compensation Committee, independent consultant Compensia, and peer benchmarking to set base salary, bonuses and option grants, with an overall target positioned below median given the company’s size. The vote is advisory only but the Compensation Committee has committed to consider the outcome when setting future compensation; historically such votes provide a governance signal about shareholder acceptance of pay practices. Key considerations for investors include the heavy use of stock options (time-based vesting for the CEO and other executives rather than performance-contingent awards), the presence of clawback policy, and the committee’s use of an independent consultant to benchmark pay. The Company's recent 'Compensation Actually Paid' metrics show volatility driven by equity valuation changes, which may explain management’s reliance on options and the Committee’s focus on retention. Investors should evaluate whether the current mix of cash and equity, the absence of meaningful performance vesting on recent grants, and total pay positioning appropriately align executives with long-term shareholder value. Given the Board’s unanimous recommendation and consultant involvement, approval would signal shareholder acquiescence to the current program; dissent would signal concern and could prompt Committee reconsideration in future cycles.